Antengene to Present Phase II Data for ATG-022 and Phase Ib/II Data for ATG-037 at ESMO 2026 — Antengene Corporation Limited

Event summary

Antengene will present Phase II data for ATG-022 (Claudin 18.2 ADC) in advanced gastric and gastroesophageal junction cancer at ESMO 2026.
Phase Ib/II data for ATG-037 (oral CD73 inhibitor) combined with pembrolizumab in checkpoint inhibitor-resistant melanoma will also be presented.
Presentations are scheduled for October 24th and 25th, 2026, at the IFEMA MADRID Convention Center in Madrid, Spain.
Antengene has obtained 33 investigational new drug (IND) approvals in the U.S. and Asia, and NDA approvals in 10 Asia Pacific markets.

The big picture

Antengene's presentation of clinical data for ATG-022 and ATG-037 at ESMO 2026 underscores the company's focus on developing innovative therapies for oncology. The results could influence Antengene's strategic direction, particularly in expanding its commercial footprint in Asia Pacific markets where it has already secured NDA approvals. The broader industry trend of targeting specific cancer biomarkers with antibody-drug conjugates and small-molecule inhibitors highlights the competitive landscape Antengene operates within.

What we're watching

Clinical Efficacy: How the Phase II data for ATG-022 and Phase Ib/II data for ATG-037 will impact their development timelines and regulatory pathways.
Market Positioning: Whether Antengene can leverage these results to strengthen its position in the competitive oncology market.
Partnership Dynamics: The pace at which Antengene's partnerships with UCB and K2 Therapeutics will advance its TCE programs.